Join
Live feed
·
PRReleasevia Quantisnow
Delcath Systems Inc. logo

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

ByQuantisnow·Wall Street's wire, on your screen.
DCTH· Delcath Systems Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DCTH (Delcath Systems Inc.) and more on Quantisnow.